Table 4.
Groups | I | II | III | IV | V | VI |
---|---|---|---|---|---|---|
SOD (U/mgprot) | 24.427 ± 2.570 | 14.139 ± 1.479a | 18.307 ± 1.937ab | 24.200 ± 2.850b | 18.750 ± 2.681ab | 14.014 ± 2.690a |
MDA (nmol/mgprot) | 3.616 ± 0.249 | 3.972 ± 0.159a | 3.690 ± 0.119b | 3.573 ± 0.201b | 2.813 ± 0.238 | 3.893 ± 0.209a |
GSH-PX (U/mgprot) | 102.977 ± 9.409 | 81.511 ± 5.276a | 106.914 ± 11.308b | 103.254 ± 20.596b | 83.769 ± 7.764a | 84.046 ± 8.010a |
Group I: control; Group II: model; Group III: pioglitazone; Group IV: high dose of TangGanJian (TGJ); Group V: middle dose of TGJ; Group VI: low dose of TGJ.
Data are expressed as mean ± standard deviation.
ap < 0.05 compared with the control group.
bp < 0.05 compared with the model group.